Čeština
|
Dansk
|
Deutsch
|
English
|
Español
|
Français
|
Italiano
|
Nederlands
|
Norsk
|
Polski
|
Português
|
Pусский
|
Suomi
|
Svenska
|
US
EHDN2016
CHOROBA
SIEĆ
REGISTRY
PROJEKTY
ZALOGUJ
Experimental Rx
-
Aktualności
Projekt
Sponsor
Komitet Wykonawczy
Arnesen
Blumenstein
Burgunder
Craufurd
Humbert
Jones
Kremer
Reilmann
Roos
Rosser
Weydt
Capper-Loup
Feihle
Levey
McLean
Dokumenty
Writing Committee Strategic ...
Komitet Naukowy
Becanovic
Busse
Frontali
Giorgini
Holmans
Mariotti
Norremolle
Reetz
Rickards
Saft
van Duijn
Valenza
Verellen
Dokumenty
Centralny Ośrodek Koordy...
Krajowe Ośrodki Koordyna...
Fellowship Programme
Constitution
Article 1
Article 2
Article 3
Article 4
Article 5
Article 6
Article 7
Article 8
Article 9
Article 10
Article 11
Article 12
Documents
Voting/Nomination
Członkostwo
Request
Lokalizacje
Austria
Belgia
Czech Republic
Dania
Finlandia
Francia
Niemcy
Ireland
Włochy
Holandia
Norwegia
Polska
Portugalia
Russia
Hiszpania
Szwecja
Szwajcaria
Zjednoczone Królestwo Wielk...
Outside Europe
Seoul
Singapore
Sydney
Grupy Robocze
Advanced HD
Dates
Meetings
Behavioural Phenotype
Dates
Meetings
Psycho appr. & interv. Sub...
Biological Modifiers
Dates
Meetings
Biomarkers
Dates
Meetings
Brain and Tissue Banking
Cognitive Phenotype
Dates
Meetings
Environmental Modifiers
Dates
Meetings
Functional Ability
Dates
Meetings
Genetic Testing
Dates
Meetings
Genetic Modifiers
Dates
Meetings
Health Economics
Imaging
Dates
Meetings
Juvenile HD
Dates
Motor Phenotype
Neuroprotective Therapy
Physiotherapy
Dates
Meetings
Quality of Life
Dates
Meetings
Standard of Care
Dates
Meetings
Dieticians
SALT
Dental care
Occupational
Surgical Approaches
Symptomatic Research
Dates
Meetings
Young Adults
Events
EHDN 2016
EHDN 2014
Announcement
Introduction
Registration
Programme Fri
Programme Sat
Programme Sun
Additional Meetings
CME points
Sponsoring
Travel Information
Hotel Booking
Reimbursement
Social Activities
Abstract Submission
Contacts
Feedback
EHDN 2012
Introduction
Announcement
Programme Fri
Programme Sat
Programme Sun
Additional Meetings
Important Dates
Registration
Travel & Accommodation
EHA Registration
EHA Programme
Reception Dinner
About Stockholm
Abstract Submission
Reimbursement
Documents
Handouts
Presentations
Posters
Pathogenic mechanisms
Animal models
Choreatic disorders - no...
Genetic modifiers
Wet Biomarkers
Imaging
Clin characteristics
Clin char-motor
Clin char-cognitive
Clin char - behaviour
Clin char-other
Clinical studies
Genetic testing
Clinical care
Experimental Rx
Clinical Rx
Non-scientific
Contacts
Feedback & Evaluation
EHDN 2010
Introduction
Programme I
Programme II
Additional Meetings
Registration
EHA Programme
EHA Registration
Plenary Dinner
Social Programme
Important Dates
Abstract Submission
Reimbursement
Hotel Booking
Travel and Location
Congress & Meeting Ven...
Travel Information
Accommodation
About Prague
Documents
Committees
Contact
Feedback & Evaluation
EHDN 2008
EHDN 2007
EHDN 2006
EHDN 2005
EHDN 2004
Szukaj
Formularz
Czat
Listy adresów
Newsletter
Job Offers
data
description
size
autor
dokument
04.08.26
In vivo efficacy of (CUG)n oligonucleotides to treat HD
32 kB
anonymous
p02-in-vivo-efficacy-oligonucleotides
04.08.26
Antisense oligonucleotide mediated transcript reduction and modulation – the European approach to develop a therapy for Huntington Disease
32 kB
anonymous
p01-antisense-oligonucleotide-transcript
04.08.26
Reducing toxic n-terminal Huntingtin fragments in HD using exon skipping
32 kB
anonymous
p03-exon-skipping
04.08.26
A Huntingtin peptide inhibits polyQ-hHtt associated defects
32 kB
anonymous
p04-polyq-hhtt-associated-defects
04.08.26
Astrocytes affect neuroprotection: Glatiramer acetate in Huntington`s Disease therapy
32 kB
anonymous
p07-glatiramer-acetate
04.08.26
Olesoxime improves specific features of the HD pathology
32 kB
anonymous
p06-olesoxime
04.08.26
Analysis of Nrf2-downstream targets after fumarate treatment in dorsal root ganglia – an anti-inflammatory therapy in neurodegenerative disease?!
32 kB
anonymous
p08-analysis-of-nrf2
Folder contains 7 dokumenty.
about us
|
privacy statement
|
disclaimer
|
terms of use